CERA

unofficial impact factor 1.46
Search for
Advanced search
Cost Effectiveness and Resource Allocation
Tools
Share this article
Open Access Highly Access

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

Werner A Scherbaum, Gordon Goodall, Katrina M Erny-Albrecht, Massimo Massi-Benedetti, Erland Erdmann and William J Valentine*

Cost Effectiveness and Resource Allocation 2009, 7:9 doi:10.1186/1478-7547-7-9

Accesses  

  • Last 30 days: 84 accesses
  • Last 365 days: 1576 accesses
  • All time: 5512 accesses

Cited by

Google Scholar: View citations

PubMed Central: View citations